Foreign Collusion, Naked Shorting (Counterfeiting) & Money Laundering — All Illicit Wealth
Pan-Mass Challenge Raises Record $63 Million for Dana-Farber
Candid, 23 October 2019
The Dana-Farber Cancer Institute in Boston has announced a record $63 million gift from the Pan-Mass Challenge, an annual two-day cycling event that raises funds for adult and pediatric cancer research and patient care at Dana-Farber Continue reading “Article: Pan-Mass Challenge Raises Record $63 Million for Dana-Farber”
H.C. Wainwright & Co. Is Once Again Ranked #1 by PlacementTracker
BusinessWire, 22 October 2019
H.C. Wainwright & Co., LLC, announced its #1 Ranking by transaction volume during the third quarter of 2019, maintaining the Firm’s top position for 18 consecutive quarters, in PlacementTracker’s Market League Tables.
In addition to being the #1 Investment Bank for CMPO, RD and PIPE transactions, H.C. Wainwright executed 150 transactions in the first three quarters of 2019 totaling $5.5 Billion in transaction value. The H.C. Wainwright team has been the #1 ranked underwriter/placement agent by deal volume cumulatively since 1998.
Comment: This company is alleged to be one of the top front-runners helping naked short sellers destroy promising companies.
Learn more: HCWainwright @ NSS
Pan-Mass Challenge Sets Record for Donations
NewsCenter, 22 October 2019
The Pan-Mass Challenge announced their largest financial gift ever given to the Dana-Farber Cancer Institute. The record breaking $63 million check exceeds this year’s $60 million goal and brings the PMC’s 40 year fundraising total to $717 million.
The 40th Annual Pan-Mass Challenge bike-a-thon was held in early August, with the route going through Cape Cod all the way to Provincetown.
The PMC is the nation’s most successful single-event athletic fundraiser and donates 100 percent of every rider raised dollar to Dana-Farber, a world leader in adult and pediatric cancer treatment and research. Continue reading “Article: Pan-Mass Challenge Sets Record for Donations”
Ex-Deutsche Bank Traders Must Face Spoofing Case, Judge Says
Janan Hanna
Bloomberg, 21 October 2019
The criminal case against two former Deutsche Bank AG employees accused of fraudulent and manipulative precious-metals trading can proceed, after a federal judge on Monday rejected their request for dismissal.
U.S. District Judge John J. Tharp in Chicago said prosecutors had properly used the wire-fraud statute to charge James Vorley and Cedric Chanu with spoofing, part of an alleged multiyear scheme to defraud other traders on the Commodity Exchange Inc., a venue run by CME Group Inc.’s Chicago Mercantile Exchange.
Brian Monroe, 17 October 2019
UBS pays $11 million to settle Italian money laundering probe, tied to tax fracas An Italian judge has accepted a request by UBS to pay more than 10 million euros ($11 million) to settle a money-laundering investigation, ending one of the Swiss bank’s biggest legal headaches in Europe, just the latest in a series of international probes and settlements tied to financial crime and compliance failures.
UBS has been grappling with two separate probes in Italy and a court case in France over allegations it enabled cross-border tax cheats to hide assets in Switzerland.
The judge on Thursday accepted the payment of 2.125 million euros as “agreed penalty” to close the case while also seizing 8.175 million euros as profit from the alleged money-laundering, two sources with direct knowledge of the matter said.
The settlement, which by Italian law is not an admission of guilt, was requested by UBS in July, after a deal with Italian prosecutors. Last June, the Swiss bank paid 101 million euros to settle its other Italian case, a related financial investigation, with tax authorities. Continue reading “Article: Fincrime Briefing: UBS pays to settle laundering probe, U.S., South Korea take down largest crypto-fueled child exploitation site, DOJ guidance on fines when you can’t pay, and more”
Form S-1/A Bionano Genomics, Inc
EDGARFILINGS LTD, 17 October 2020
We are offering 5,265,000 shares of our common stock and common warrants to purchase an aggregate of 5,265,000 shares of our common stock (and the shares of common stock that are issuable from time to time upon exercise of the warrants). We are also offering to certain purchasers whose purchase of shares of common stock in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock immediately following the consummation of this offering, the opportunity to purchase, if any such purchaser so chooses, pre-funded warrants, in lieu of shares of common stock that would otherwise result in such purchaser’s beneficial ownership exceeding 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock. Each pre-funded warrant will be exercisable for one share of our common stock. Continue reading “Article: Form S-1/A Bionano Genomics, Inc”
Wirecard’s suspect accounting practices revealed
Dan McCrum
Financial Times, 15 October 2019
FT Investigation: internal documents from the payments company point to a concerted effort to fraudulently inflate sales and profits
Comment: Dan McCrum is strongly suspected of being a shill for naked short sellers, and appears to be one of several journalists — others work for the Wall Street Journal — who routinely bash companies to further illegal naked short selling campaign. He should be deeply investigated.
Bausch Health jumps after short seller says stock could double
Cristin Flanagan, 15 October 2019
Shares of Bausch Health Cos. jumped as much as 5.5 per cent intraday after a short-seller changed his tune and said the stock could nearly double. Also, Bausch shed another bear as Wells Fargo realigned its coverage. Andrew Left’s Citron Research set a price target of US$40, more than 80 per cent above current trading. The report comes more than four years after the short-seller’s 2015 call, when Left accused Bausch, then known as Valeant Pharmaceuticals, of being “Enron part deux.”
Bausch shares have come down more than 90 per cent from 2015. The stock “still trades with a ‘Valeant discount’ despite new management’s 180-degree turn,” the Citron report said. Bausch’s Nov. 4 earnings may be when Wall Street finally takes notice, it added.
Continue reading “Article: Bausch Health jumps after short seller says stock could double”
Citron Calls Bausch Health — Formerly Valeant — The ‘Textbook Turnaround’
Wayne Duggan, 15 October 2019
Three years after Citron Research called Valeant the “pharmaceutical Enron,” the firm said Tuesday that it’s time to give Valeant successor Bausch Health Companies Inc BHC 0.06% the credit it is due for its rebranding and turnaround efforts.
On Tuesday, Citron Research’s Andrew Left said CEO Joe Papa has done a spectacular job since taking over less than four years ago. In the past three years alone, management has paid down about $8 billion in debt, vastly improving the company’s balance sheet and putting them in a position of financial flexibility.
“In 2019, the debt has become manageable and the company is gaining momentum with recent, successful launches of new drugs, consistent with its ‘pivot to offense,’” Left said.
Continue reading “Article: Citron Calls Bausch Health — Formerly Valeant — The ‘Textbook Turnaround’”
BAUSCH HEALTH – THE TEXTBOOK TURNAROUND Giving Credit Where Credit is Due – Target Price $40
Citron Research, 15 October 2019
It was four years ago this month that Citron wrote a series of articles that were instrumental in the unraveling of the Pearson-era Valeant business model. In quick manner the stock has declined by 90% from its highs as the scandals unraveled and many questioned the sustainability of the equity.
Four years later BHC still trades with a “Valeant discount” despite new management’s 180-degree turn of corporate culture. To add to the artificially depressed share price, Bausch has been unjustly grouped with Specialty Pharma despite having ZERO opioid exposure and minimal exposure to the generics market.
Citron believes this quarter (reporting on Nov 4) will force Wall St. to finally take notice of BHC’s “pivot to offense”. Once this is considered along with the acknowledgment of the recent M&A spree in pharma, even David Maris will have to admit that BHC is on its way to $40.
Continue reading “Article: BAUSCH HEALTH – THE TEXTBOOK TURNAROUND Giving Credit Where Credit is Due – Target Price $40”
9 October 2019
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Overstock.com, Inc. ( OSTK) from May 9, 2019 through September 23, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Overstock investors under the federal securities laws.
8 October 2019
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Overstock.com, Inc. (“Overstock” or the “Company”) (NASDAQ: OSTK) securities between May 9, 2019 and September 23, 2019, inclusive (the “Class Period”). Overstock investors have until November 26, 2019 to file a lead plaintiff motion.
According to Byrne, his departure and stock sale are unrelated to his FBI activities or what he has described as a romantic tryst with an alleged Russian spy, Maria Butina, though he says those matters will become a huge story sometime soon. Byrne in his interview with FOX Business said he didn’t want to dwell on spycraft (“I’m supposed to be keeping quiet [on] all that political stuff,” he said), adding cryptically that the full story “will break this year and it will be 100 times bigger than Watergate … it’s political fraud conducted by the deep state against the republic, against Democrats and Republicans … I was asked to set up Hillary Clinton,” all of which he declined to elaborate on.
CFTC Settles With Morgan Stanley & Mitsubishi, $1.4 & $0.4 Million Fines For Spoofing Gold & Silver
Ottawa Bullion, 3 October 2019
The U.S. Commodity Futures Trading Commission today announced that civil enforcement actions were filed and simultaneously settled against two trading firms and one bank for violating the Commodity Exchange Act’s (CEA) prohibition on spoofing (bidding or offering with the intent to cancel the bid or offer before execution). These cases were brought in connection with the Division of Enforcement’s Spoofing Task Force.
2 October 2019
Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal class action securities lawsuit has been filed in the United States District Court for the District of Utah on behalf of shareholders of Overstock.com, Inc. (“Overstock” or the “Company”) (NASDAQ: OSTK) who purchased shares between May 9, 2019, and September 23, 2019, inclusive (the “Class Period”).
THE DOLLAR HAS NO INTRINSIC VALUE : DO YOUR ASSETS?
